Research Topics
Genomes and Genes | J S MillarSummaryAffiliation: University of Pennsylvania Country: USA Publications
| Collaborators
|
Detail Information
Publications
Determining hepatic triglyceride production in mice: comparison of poloxamer 407 with Triton WR-1339John S Millar
Institute for Translational Medicine and Therapeutics, University of Pennsylvania, Philadelphia, PA 19104, USA
J Lipid Res 46:2023-8. 2005..Another nonionic detergent, poloxamer 407 (P-407), also inhibits LPL. In these studies, we demonstrate that P-407 is comparable to Triton in the determination of TG production but without the unwanted side effects of Triton...- Selective peroxisome proliferator-activated receptor-γ modulation to reduce cardiovascular risk in patients with insulin resistanceTongwei Yew
Division of Endocrinology, Department of Medicine, National University Health System, Singapore, 1E Kent Ridge Road, Level 10, Singapore
Recent Pat Cardiovasc Drug Discov 7:33-41. 2012..Recent patents of novel approaches for the use of PPAR-γ related compounds with the potential for this improved risk-benefit ratio are discussed... 
Effect of rosiglitazone on HDL metabolism in subjects with metabolic syndrome and low HDLJohn S Millar
Department of Pharmacology, University of Pennsylvania, Philadelphia, PA 19104, USA
J Lipid Res 52:136-42. 2011..The change in HDL-C in response to rosiglitazone treatment was unrelated to effects on apoA-I, instead being related to the change in the metabolism of apoA-II...- Short-term treatment with high-dose atorvastatin reduces LDL cholesterol but shows no anti-inflammatory effects in normolipidemic subjects with normal CRP levelsJohn S Millar
The Institute for Translational Medicine and Therapeutics, The University of Pennsylvania, Philadelphia, USA
Clin Transl Sci 3:140-6. 2010.... - Effects of nevirapine and efavirenz on HDL cholesterol levels and reverse cholesterol transport in miceJunichiro Tohyama
Institute for Translational Medicine and Therapeutics, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
Atherosclerosis 204:418-23. 2009..Studies were conducted to test the hypothesis that NNRTIs have a beneficial effect on HDL-C and reverse cholesterol transport (RCT)... - Potent and selective PPAR-alpha agonist LY518674 upregulates both ApoA-I production and catabolism in human subjects with the metabolic syndromeJohn S Millar
Departments of Pharmacology, University of Pennsylvania, 652 BRB II III, 421 Curie Blvd, Philadelphia, PA 19104, USA
Arterioscler Thromb Vasc Biol 29:140-6. 2009..We sought to determine the effect of a potent and highly specific PPAR-alpha agonist, LY518674, on apoA-I, apoA-II, and apoB-100 kinetics in humans with metabolic syndrome and low levels of HDL cholesterol (C)... - Effects of the cholesteryl ester transfer protein inhibitor torcetrapib on VLDL apolipoprotein E metabolismJohn S Millar
Department of Pharmacology, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
J Lipid Res 49:543-9. 2008..Adding torcetrapib to atorvastatin treatment increases the VLDL apoE content, likely leading to decreased conversion of VLDL to LDL, reduced LDL production, and lower levels of circulating VLDL and LDL... - The sialylation of plasma lipoproteinsJ S Millar
Department of Medicine, University of Pennsylvania, 621 BRB II III, 421 Curie Boulevard, Philadelphia, PA 19104 6160, USA
Atherosclerosis 154:1-13. 2001..Manipulations of the sialylation of apolipoproteins and of the quantity of apolipoproteins and gangliosides on lipoproteins will be useful methods in determining the role of lipoprotein sialic acid in the development of atherosclerosis... - Short-term overexpression of DGAT1 or DGAT2 increases hepatic triglyceride but not VLDL triglyceride or apoB productionJohn S Millar
Department of Pharmacology, University of Pennsylvania, Philadelphia, PA, USA
J Lipid Res 47:2297-305. 2006..In the presence of adequate cytoplasmic lipid stores, factors other than triglyceride synthesis are rate-limiting for VLDL production... - Effects of the cholesteryl ester transfer protein inhibitor torcetrapib on apolipoprotein B100 metabolism in humansJohn S Millar
Institute for Translational Medicine and Therapeutics, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
Arterioscler Thromb Vasc Biol 26:1350-6. 2006..The goal of the present study was to define the kinetic mechanism(s) by which CETP inhibition reduces levels of apoB-containing lipoproteins... - Normal production rate of apolipoprotein B in LDL receptor-deficient miceJohn S Millar
Department of Medicine, University of Pennsylvania, Philadelphia 19104, USA
Arterioscler Thromb Vasc Biol 22:989-94. 2002..These results indicate that the LDL receptor has no effect on the production rate of VLDL triglyceride or apoB in vivo in mice... - Complete deficiency of the low-density lipoprotein receptor is associated with increased apolipoprotein B-100 productionJohn S Millar
Department of Medicine, University of Pennsylvania, 644 BRB II III, 421 Curie Blvd, Philadelphia, PA 19104, USA
Arterioscler Thromb Vasc Biol 25:560-5. 2005..We addressed the role of the low-density lipoprotein (LDL) receptor in determining clearance rates and production rate (PR) of apolipoprotein B (apoB) in humans... - Increased atherosclerosis in mice lacking apolipoprotein A-I attributable to both impaired reverse cholesterol transport and increased inflammationRyan E Moore
Institute for Translational Medicine and Therapeutics, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
Circ Res 97:763-71. 2005.... - Endothelial lipase promotes the catabolism of ApoB-containing lipoproteinsUli C Broedl
University of Pennsylvania, Philadelphia, PA, USA
Circ Res 94:1554-61. 2004..In light of these results, inhibition of EL has the potential to raise levels of atherogenic lipoproteins in addition to HDL-C levels... 
Knockdown of acyl-CoA:diacylglycerol acyltransferase 2 with antisense oligonucleotide reduces VLDL TG and ApoB secretion in miceYing Liu
Institute for Translational Medicine and Therapeutics, University of Pennsylvania, Philadelphia, PA 19104 6160, USA
Biochim Biophys Acta 1781:97-104. 2008..Our findings indicate that the majority of TG destined for secretion by liver is synthesized by DGAT2 and suggests that DGAT2 may be a therapeutic target for treatment of hypertriglyceridemia, hepatic steatosis and obesity...- Modulation of HDL metabolism by the niacin receptor GPR109A in mouse hepatocytesXiaoyu Li
Institute for Translational Medicine and Therapeutics and Cardiovascular Institute, University of Pennsylvania School of Medicine, Philadelphia, 19104, USA
Biochem Pharmacol 80:1450-7. 2010..These results indicate that niacin-mediated activation of GP109A in liver lowers ABCA1 expression leading to reduced hepatic cholesterol efflux to HDL... - Endothelial lipase is less effective at influencing HDL metabolism in vivo in mice expressing apoA-IIUli C Broedl
Department of Medicine and Center for Experimental Therapeutics, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
J Lipid Res 47:2191-7. 2006..We conclude that the presence of apoA-II on HDL particles inhibits the ability of EL to influence the metabolism of HDL in vivo... - The effect of PPAR-alpha agonism on apolipoprotein metabolism in humansAshish Shah
University of Pennsylvania, Depts of Medicine and Pharmacology, 652 BRB II III, 421 Curie Blvd, Philadelphia, PA 19104, United States
Atherosclerosis 210:35-40. 2010..However, the benefit of the enhanced turnover of HDL apoA-I in response to PPAR-alpha activation remains to be determined... - Novel ENU-induced point mutation in scavenger receptor class B, member 1, results in liver specific loss of SCARB1 proteinIoannis M Stylianou
School of Medicine, Institute for Translational Medicine and Therapeutics, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America
PLoS ONE 4:e6521. 2009..This new Scarb1 model may help further our understanding of post-translational and tissue-specific regulation of SCARB1 that may aid the important clinical goal of raising functional HDL... - Overexpression of apolipoprotein F reduces HDL cholesterol levels in vivoWilliam R Lagor
Institute for Translational Medicine and Therapeutics, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
Arterioscler Thromb Vasc Biol 29:40-6. 2009..It is also known as lipid transfer inhibitor protein (LTIP) based on its ability to inhibit lipid transfer between lipoproteins ex vivo. We sought to investigate the role of ApoF in HDL metabolism... - Endogenously produced endothelial lipase enhances binding and cellular processing of plasma lipoproteins via heparan sulfate proteoglycan-mediated pathwayIlia V Fuki
Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
J Biol Chem 278:34331-8. 2003..002 via LpL. In summary, EL mediates binding and uptake of plasma lipoproteins via a process that is independent of its enzymatic activity, requires cellular heparan sulfate proteoglycans, and is regulated by ligand clustering... - Both the peroxisome proliferator-activated receptor delta agonist, GW0742, and ezetimibe promote reverse cholesterol transport in mice by reducing intestinal reabsorption of HDL-derived cholesterolFrançois Briand
Institute for Translational Medicine and Therapeutics, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA
Clin Transl Sci 2:127-33. 2009..In conclusion, PPARdelta activation enhances excretion of macrophage or HDL-derived cholesterol in feces through reduced NPC1L1 expression in mice, comparable to the effect of ezetimibe... - Inhibition of endothelial lipase causes increased HDL cholesterol levels in vivoWeijun Jin
Department of Medicine and Center for Experimental Therapeutics, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA
J Clin Invest 111:357-62. 2003..We conclude that inhibition of EL results in increased HDL-C levels and that EL is an important enzyme in the physiological regulation of HDL metabolism... - Hepatic proprotein convertases modulate HDL metabolismWeijun Jin
Department of Pharmacology, Institute for Translational Medicine and Therapeutics, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
Cell Metab 6:129-36. 2007..The hepatic PC-ANGPTL3-EL-HDL pathway is therefore a novel mechanism controlling HDL metabolism and cholesterol homeostasis... - Pathways by which reconstituted high-density lipoprotein mobilizes free cholesterol from whole body and from macrophagesMarina Cuchel
Institute for Translational Medicine and Therapeutics, University of Pennsylvania School of Medicine, Maloney Building, Room 8039, 3600 Spruce Street, Philadelphia, PA 19104, USA
Arterioscler Thromb Vasc Biol 30:526-32. 2010..We performed studies to identify the underlying molecular mechanisms by which rHDL promote FC mobilization from whole body in vivo and macrophages in vitro... - Apolipoprotein A-I deficiency results in markedly increased atherosclerosis in mice lacking the LDL receptorRyan E Moore
University of Pennsylvania School of Medicine, 654 BRB II/III, 421 Curie Blvd, Philadelphia, PA 19104, USA
Arterioscler Thromb Vasc Biol 23:1914-20. 2003..CONCLUSIONS: These results demonstrate that despite normal levels of HDL-C, apoA-I deficiency is associated with a significant loss of protection from the formation of atherosclerosis in LDLR-/- mice fed a chow diet... - Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemiaMarina Cuchel
University of Pennsylvania School of Medicine, Philadelphia, USA
N Engl J Med 356:148-56. 2007..Inhibition of the microsomal triglyceride transfer protein may be effective in reducing cholesterol levels in these patients... - The metabolism of apolipoproteins (a) and B-100 within plasma lipoprotein (a) in human beingsJennifer L Jenner
Lipid Metabolism Laboratory, Jean Mayer USDA Human Nutrition Research Center on Aging, Tufts University, Boston, MA 02111, USA
Metabolism 54:361-9. 2005.... - Effects of cholesteryl ester transfer protein inhibition on high-density lipoprotein subspecies, apolipoprotein A-I metabolism, and fecal sterol excretionMargaret E Brousseau
Lipid Metabolism Laboratory, JM USDA HNRCA at Tufts University and Tufts New England Medical Center, Boston, Mass 02111, USA
Arterioscler Thromb Vasc Biol 25:1057-64. 2005..The present study was designed to address these issues... - Lipoprotein [a] is cleared from the plasma primarily by the liver in a process mediated by apolipoprotein [a]William J Cain
Department of Biological Sciences, University of Delaware, Newark, DE, USA
J Lipid Res 46:2681-91. 2005..Our studies indicate that apo[a] is the primary ligand that mediates Lp[a] uptake and plasma clearance...